About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CMT-07-08: The PROstate Bed Evaluation Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT00763152

CMT-07-08: The PROstate Bed Evaluation Study

This is an observational study to collect placement and tracking data for patients who have the Calypso transponders implanted into the peri-prostatic tissue.

Lead sponsor: Varian, a Siemens Healthineers Company•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Varian, a Siemens Healthineers Company

Use of Real-time tracking using Calypso Electromagnetic Beacons in the prostatic bed of patients receiving radiotherapy following radical prostatectomy.

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•1. Patients with recurrence of prostate cancer following radical prostatectomy for prostate adenocarcinoma
•2. Patients with initially undetectable PSA following prostatectomy for prostate adenocarcinoma with subsequent PSA relapse
•3. Patients being planned for radiation therapy
•4. Patient is being planned for implant with Calypso Transponders in the prostate bed
•5. No evidence of distant metastases
•6. Age ≥ 18 years
•7. Informed consent

Exclusion Criteria

•1. The patient has received other investigational therapy in the last 60 days
•2. The patient has previously been implanted with permanent beacon transponders
•3. The patient has a prosthetic implant in the pelvic region that contain metal or conductive materials
•4. The patient has any other medical or other condition that would, in the investigator's opinion, make them a poor candidate for the study

Related studies

Selecting Hypoxic Tumours for Treatment Modification

NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer

Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)

NCT07580196 · Prostate Cancer

RECRUITINGPhase 1/2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 15, 2015Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment12

Start dateSep 2008

Last updatedOct 15, 2015

Condition

Prostate Cancer

Locations shown

21C Oncology - Scottsdale

Scottsdale, Arizona

Metropolitan Uro-Rad

St Louis, Missouri

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions